Glen Santangelo
Stock Analyst at Jefferies
(2.52)
# 2,384
Out of 4,981 analysts
79
Total ratings
47.06%
Success rate
2.87%
Average return
Main Sectors:
Stocks Rated by Glen Santangelo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HQY HealthEquity | Maintains: Buy | $130 → $134 | $92.49 | +44.88% | 6 | Sep 3, 2025 | |
| TDOC Teladoc Health | Maintains: Hold | $10 → $8 | $7.68 | +4.17% | 7 | Apr 21, 2025 | |
| ANIP ANI Pharmaceuticals | Initiates: Buy | $80 | $97.95 | -18.33% | 1 | Mar 14, 2025 | |
| VTRS Viatris | Maintains: Buy | $15 → $13 | $9.96 | +30.52% | 4 | Mar 7, 2025 | |
| WAY Waystar Holding | Initiates: Buy | $51 | $37.36 | +36.51% | 1 | Feb 11, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $4 → $6 | $7.49 | -19.89% | 2 | Jan 29, 2025 | |
| NVST Envista Holdings | Maintains: Hold | $20 → $22 | $21.01 | +4.71% | 1 | Jan 23, 2025 | |
| XRAY DENTSPLY SIRONA | Downgrades: Hold | $30 → $20 | $13.54 | +47.77% | 2 | Jan 23, 2025 | |
| PCRX Pacira BioSciences | Maintains: Buy | $15 → $18 | $27.12 | -33.63% | 5 | Sep 24, 2024 | |
| PGNY Progyny | Maintains: Buy | $31 → $24 | $22.51 | +6.62% | 4 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $14 → $23 | $55.50 | -58.56% | 4 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $23 | $19.93 | +15.40% | 4 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $41 → $44 | $37.33 | +17.87% | 3 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $18.53 | -8.26% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $230 | $148.20 | +55.20% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $4.83 | +1,970.39% | 2 | Dec 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $70 | $28.06 | +149.47% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $55 | $24.81 | +121.68% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $11.84 | +35.14% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $14 | $5.63 | +148.89% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $46 | $71.03 | -35.24% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $28 | $3.13 | +794.57% | 2 | Mar 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $24.19 | +189.38% | 1 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $120 | $6.64 | +1,707.23% | 3 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $2 | $2.56 | -21.88% | 1 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $4.19 | +1,021.72% | 1 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $4.15 | +768.52% | 1 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $74.98 | - | 3 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $173 → $169 | $711.42 | -76.24% | 5 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $152.24 | - | 4 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $82 | $69.01 | +18.82% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $250 | $131.56 | +90.03% | 1 | Dec 8, 2017 |
HealthEquity
Sep 3, 2025
Maintains: Buy
Price Target: $130 → $134
Current: $92.49
Upside: +44.88%
Teladoc Health
Apr 21, 2025
Maintains: Hold
Price Target: $10 → $8
Current: $7.68
Upside: +4.17%
ANI Pharmaceuticals
Mar 14, 2025
Initiates: Buy
Price Target: $80
Current: $97.95
Upside: -18.33%
Viatris
Mar 7, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $9.96
Upside: +30.52%
Waystar Holding
Feb 11, 2025
Initiates: Buy
Price Target: $51
Current: $37.36
Upside: +36.51%
Xeris Biopharma Holdings
Jan 29, 2025
Reiterates: Buy
Price Target: $4 → $6
Current: $7.49
Upside: -19.89%
Envista Holdings
Jan 23, 2025
Maintains: Hold
Price Target: $20 → $22
Current: $21.01
Upside: +4.71%
DENTSPLY SIRONA
Jan 23, 2025
Downgrades: Hold
Price Target: $30 → $20
Current: $13.54
Upside: +47.77%
Pacira BioSciences
Sep 24, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $27.12
Upside: -33.63%
Progyny
Sep 19, 2024
Maintains: Buy
Price Target: $31 → $24
Current: $22.51
Upside: +6.62%
Jun 27, 2024
Maintains: Hold
Price Target: $14 → $23
Current: $55.50
Upside: -58.56%
Jun 27, 2024
Maintains: Buy
Price Target: $19 → $23
Current: $19.93
Upside: +15.40%
Jun 7, 2024
Upgrades: Buy
Price Target: $41 → $44
Current: $37.33
Upside: +17.87%
Dec 19, 2023
Initiates: Buy
Price Target: $17
Current: $18.53
Upside: -8.26%
Dec 19, 2023
Assumes: Buy
Price Target: $230
Current: $148.20
Upside: +55.20%
Dec 15, 2023
Reiterates: Buy
Price Target: $100
Current: $4.83
Upside: +1,970.39%
Jul 25, 2023
Reinstates: Buy
Price Target: $70
Current: $28.06
Upside: +149.47%
Oct 21, 2022
Initiates: Hold
Price Target: $55
Current: $24.81
Upside: +121.68%
Oct 21, 2022
Initiates: Buy
Price Target: $16
Current: $11.84
Upside: +35.14%
Oct 21, 2022
Assumes: Buy
Price Target: $14
Current: $5.63
Upside: +148.89%
May 18, 2022
Maintains: Buy
Price Target: $78 → $46
Current: $71.03
Upside: -35.24%
Mar 17, 2022
Upgrades: Buy
Price Target: $31 → $28
Current: $3.13
Upside: +794.57%
Dec 2, 2021
Initiates: Buy
Price Target: $70
Current: $24.19
Upside: +189.38%
Dec 2, 2021
Initiates: Hold
Price Target: $120
Current: $6.64
Upside: +1,707.23%
Dec 2, 2021
Initiates: Hold
Price Target: $2
Current: $2.56
Upside: -21.88%
Dec 2, 2021
Initiates: Buy
Price Target: $47
Current: $4.19
Upside: +1,021.72%
Dec 2, 2021
Initiates: Buy
Price Target: $36
Current: $4.15
Upside: +768.52%
Mar 17, 2021
Downgrades: Neutral
Price Target: n/a
Current: $74.98
Upside: -
May 21, 2020
Maintains: Hold
Price Target: $173 → $169
Current: $711.42
Upside: -76.24%
Dec 16, 2019
Downgrades: Neutral
Price Target: n/a
Current: $152.24
Upside: -
Apr 24, 2018
Maintains: Buy
Price Target: $79 → $82
Current: $69.01
Upside: +18.82%
Dec 8, 2017
Initiates: Hold
Price Target: $250
Current: $131.56
Upside: +90.03%